168 related articles for article (PubMed ID: 23422397)
1. No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia.
Fan X; Liu E; Freudenreich O; Copeland P; Hayden D; Ghebremichael M; Cohen B; Ongur D; Goff DC; Henderson DC
J Clin Psychopharmacol; 2013 Apr; 33(2):226-30. PubMed ID: 23422397
[TBL] [Abstract][Full Text] [Related]
2. No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia.
Li J; Li X; Liu E; Copeland P; Freudenreich O; Goff DC; Henderson DC; Song X; Fan X
Schizophr Res; 2013 May; 146(1-3):40-5. PubMed ID: 23434504
[TBL] [Abstract][Full Text] [Related]
3. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
4. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial.
Bobo WV; Woodward ND; Sim MY; Jayathilake K; Meltzer HY
Schizophr Res; 2011 Aug; 130(1-3):106-13. PubMed ID: 21641776
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
Zheng W; Zhu XM; Zhang QE; Yang XH; Cai DB; Li L; Li XB; Ng CH; Ungvari GS; Ning YP; Xiang YT
Schizophr Res; 2019 Apr; 206():13-20. PubMed ID: 30573406
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory Combination Therapy for the Treatment of Schizophrenia.
Buchanan RW; Weiner E; Kelly DL; Gold JM; Chen S; Zaranski J; Blatt F; Wehring H; Carpenter WT
J Clin Psychopharmacol; 2020; 40(5):444-450. PubMed ID: 32796391
[TBL] [Abstract][Full Text] [Related]
7. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
[TBL] [Abstract][Full Text] [Related]
8. The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.
Fan X; Song X; Zhao M; Jarskog LF; Natarajan R; Shukair N; Freudenreich O; Henderson DC; Goff DC
Acta Psychiatr Scand; 2017 Nov; 136(5):465-472. PubMed ID: 28851055
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder.
McIntyre RS; Soczynska JK; Woldeyohannes HO; Miranda A; Vaccarino A; Macqueen G; Lewis GF; Kennedy SH
Bipolar Disord; 2012 Nov; 14(7):697-706. PubMed ID: 23107220
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder.
Cha DS; Best MW; Bowie CR; Gallaugher LA; Woldeyohannes HO; Soczynska JK; Lewis G; MacQueen G; Sahakian BJ; Kennedy SH; Lui JP; Mansur RB; McIntyre RS
J Affect Disord; 2017 Mar; 210():57-65. PubMed ID: 28013123
[TBL] [Abstract][Full Text] [Related]
11. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
12. A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia.
Gibson CM; Penn DL; Smedley KL; Leserman J; Elliott T; Pedersen CA
Schizophr Res; 2014 Jul; 156(2-3):261-5. PubMed ID: 24799299
[TBL] [Abstract][Full Text] [Related]
13. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
Smith RC; Jin H; Li C; Bark N; Shekhar A; Dwivedi S; Mortiere C; Lohr J; Hu Q; Davis JM
Schizophr Res; 2013 Jan; 143(1):18-24. PubMed ID: 23200554
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
[TBL] [Abstract][Full Text] [Related]
17. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.
Lee MR; Wehring HJ; McMahon RP; Linthicum J; Cascella N; Liu F; Bellack A; Buchanan RW; Strauss GP; Contoreggi C; Kelly DL
Schizophr Res; 2013 Apr; 145(1-3):110-5. PubMed ID: 23415472
[TBL] [Abstract][Full Text] [Related]
18. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
19. The effects of galantamine on psychopathology in chronic stable schizophrenia.
Conley RR; Boggs DL; Kelly DL; McMahon RP; Dickinson D; Feldman S; Ball MP; Buchanan RW
Clin Neuropharmacol; 2009; 32(2):69-74. PubMed ID: 18978489
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
